34801738|PMC8603331
{'Chemical', 'Disease', 'Species', 'Gene'}
Objective
IntroductionThe COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov2) has ravaged almost every nation across the globe (World Health Organization, 2021). In this analysis we found that the WHO score on day 5 was 48.9% lower in the Umifenovir group (P=0.019) compared to the placebo group (Figure 3 , Table 3 ).Overall, the primary and secondary endpoints are met for the Mild-asymptomatic category of patients. The trial was conducted as per the guidelines of the Central Drugs Standard Control Organization, the National regulatory authority in India.